HK Stock Market Move | HENLIUS (02696) rose nearly 6% in the afternoon. Its drug for the adjuvant treatment of stage III gastric cancer has reached its endpoint. The company plans to apply for early marketing approval for this indication.

HENLIUS (02696) rose nearly 6% in the afternoon, up 5.18% as of press time, to HKD 70.05, with a turnover of HKD 71.6472 million. On the news front, on October 9, HENLIUS announced that the company's self-developed innovative PD-1 inhibitor, Hansult (Suruli monoclonal antibody), combined with neoadjuvant/ adjuvant chemotherapy for gastric cancer in a phase III clinical study, met the preset efficacy standards and the treatment scheme was safe. It becomes the world's first treatment plan for gastric cancer perioperative period (preoperative/postoperative) to replace postoperative adjuvant chemotherapy with immunotherapy alone, achieving a significant breakthrough in this field. In view of these data results, HENLIUS plans to apply for early market approval for this indication. Dr. Zhu Jun, Executive Director and CEO of HENLIUS, said that gastrointestinal tumors are the core field of HENLIUS's deep cultivation. We will actively promote the transformation of achievements, benefit patients as soon as possible, and continue to accelerate the in-depth exploration and wide application of more innovative therapies.